Page 44 - Ram Prasad Sahu/undefined

US respiratory portfolio to drive medium term sales growth for Cipla

In the domestic market, growth is expected to come from Covid-related drugs

Mindtree ticks double-digit growth to ride on strong deal pipeline

After a strong finish to FY21, the key trigger for the stock would be the growth metrics the company will deliver in FY22

Apparel retailers on weak footing as Covid-related curbs dent sales

Higher raw material costs will put pressure on profitability

Infosys: Analysts keep the faith despite the disappointing Q4 show

Street expects an upward revision in growth guidance; valuation divergence with TCS to narrow

Domestic growth trajectory to remain strong for Glenmark in near term

Debt reduction key if the stock is to fetch higher valuation multiples

Weak product cycle could lead to further market share loss for Maruti

Higher commodity prices could worsen its margin profile

Low base, recovery in demand to drive up auto firms' Q4 earnings

Recovery in the African and Latin American markets should help exporters post better growth than the domestic market

Dr Reddy's stock sheds 4% as Sputnik V pricing, competition weigh

Access to the private market, international sales are other factors that will impact margins

Near-term growth on market share gains to remain robust for Astral Poly

Valuations, PVC price moderation may, however, keep the stock under pressure

India gets third Covid-19 vaccine as SEC clears Russia's Sputnik V

Final nod from DCGI soon, jab likely at $3/dose

Input costs and demand concerns may impact Marico in the near term

March quarter performance is expected to be strong on low base, price hikes

Near-term growth woes for Titan after strong jewellery-powered Q4

Product mix and salary reinstatement could put pressure on margins

Growth triggers, valuations drive Britannia stock; Covid impact subdued

Market share improvement, uptick in margins to sustain gains over the medium term

Demand recovery, new launches help Sobha deliver record performance

Stock gains 16 per cent on Q4 show, expectations of sharp reduction in debt

Advertising recovery, near-term gains from IPL to support Sun TV stock

Subscription growth is expected to remain healthy in the near term

US FDA nod to Teva for key specialty product to weigh on Sun Pharma

Strong US portfolio, margin gains and India business growth to support stock

Burger King India IPO: Well placed to tap the QSR opportunity in market

The Street is bullish about the long-term growth trajectory, but analysts believe the stock is factoring in the near-term upsides. Investors could look at it on dips

Happiest Minds Technologies IPO: Digital exposure buoys company

The stock surge since listing (up 225 per cent) has taken valuations to nearly 40 times its FY23 earnings estimates. Investors can look at the stock on dips

Rossari Biotech IPO: A diversified portfolio, expansion are key triggers

The expansion is expected to support growth with revenues and profits estimated to rise by 20-25 per cent over the FY20-23 period

Route Mobile IPO: Company's signal stays strong on surge in Cloud adoption

Though the growth trajectory remains strong, valuation at 51 times its FY22 earnings estimates is already factoring in most of the growth, say analysts at Edelweiss